Skip to Content

Roflumilast Pregnancy and Breastfeeding Warnings

Roflumilast is also known as: Daliresp

Medically reviewed on April 9, 2018.

Roflumilast Pregnancy Warnings

Roflumilast has been assigned to pregnancy category C by the FDA. Animal studies have failed to revealed evidence of teratogenicity. There are no controlled data in human pregnancy. Roflumilast is only recommended for use during pregnancy when benefit outweighs risk. The manufacturer recommends that roflumilast be avoided in labor and delivery.

See references

Roflumilast Breastfeeding Warnings

There is no data on the excretion of roflumilast into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Daliresp (roflumilast)." Forest Pharmaceuticals, St. Louis, MO.

References for breastfeeding information

  1. "Product Information. Daliresp (roflumilast)." Forest Pharmaceuticals, St. Louis, MO.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide